CY1112039T1 - Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης - Google Patents

Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης

Info

Publication number
CY1112039T1
CY1112039T1 CY20111101053T CY111101053T CY1112039T1 CY 1112039 T1 CY1112039 T1 CY 1112039T1 CY 20111101053 T CY20111101053 T CY 20111101053T CY 111101053 T CY111101053 T CY 111101053T CY 1112039 T1 CY1112039 T1 CY 1112039T1
Authority
CY
Cyprus
Prior art keywords
holoperidon
isomeri
variable
optical
fouoro
Prior art date
Application number
CY20111101053T
Other languages
Greek (el)
English (en)
Inventor
Dominique Grimler
Hans O Kalkman
Hequn Yin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1112039T1 publication Critical patent/CY1112039T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CY20111101053T 2001-08-31 2011-11-02 Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης CY1112039T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31639001P 2001-08-31 2001-08-31
EP02767454A EP1425272B1 (en) 2001-08-31 2002-08-30 Optical isomers of an iloperidone metabolite

Publications (1)

Publication Number Publication Date
CY1112039T1 true CY1112039T1 (el) 2015-11-04

Family

ID=23228843

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111101053T CY1112039T1 (el) 2001-08-31 2011-11-02 Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης
CY20131100058T CY1113550T1 (el) 2001-08-31 2013-01-23 Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20131100058T CY1113550T1 (el) 2001-08-31 2013-01-23 Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης

Country Status (9)

Country Link
US (4) US20050020632A1 (enExample)
EP (2) EP2305656B1 (enExample)
JP (6) JP2005504783A (enExample)
AT (1) ATE518845T1 (enExample)
CY (2) CY1112039T1 (enExample)
DK (2) DK1425272T3 (enExample)
ES (2) ES2398434T3 (enExample)
PT (2) PT2305656E (enExample)
WO (1) WO2003020707A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2463158C (en) 2001-10-30 2013-07-30 Novartis Ag Depot formulations of iloperidone and a star polymer
ATE398108T1 (de) 2002-03-27 2008-07-15 Glaxo Group Ltd Chinolinderivate und deren verwendung als 5-ht6 liganden
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
HRP20060100T3 (en) 2003-07-22 2007-03-31 Arena Pharmaceuticals Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
EP1799865B1 (en) 2004-09-30 2012-06-06 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
US20070262395A1 (en) 2006-05-11 2007-11-15 Gibbons Jasper S Memory cell access devices and methods of making the same
US8008144B2 (en) 2006-05-11 2011-08-30 Micron Technology, Inc. Dual work function recessed access device and methods of forming
BRPI0711872A2 (pt) * 2006-05-22 2011-12-06 Vanda Pharmaceuticals Inc tratamento para distúrbios depressivos
US20150259747A1 (en) 2007-03-29 2015-09-17 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
EP2134873B1 (en) 2007-03-29 2015-05-06 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US9080214B2 (en) 2007-05-18 2015-07-14 Vanda Pharmaceuticals, Inc. Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
US8652776B2 (en) 2007-09-10 2014-02-18 Vanda Pharmaceuticals, Inc. Prediction of QT prolongation based on SNP genotype
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US8729100B2 (en) * 2007-12-13 2014-05-20 Vanda Pharmaceuticals, Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
HRP20140701T1 (hr) 2007-12-13 2014-11-21 Vanda Pharmaceuticals Inc. Metoda i spoj za lijeäśenje stanja posredovanih serotoninskim receptorom
US20110061014A1 (en) 2008-02-01 2011-03-10 Energyhub Interfacing to resource consumption management devices
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
US7824986B2 (en) 2008-11-05 2010-11-02 Micron Technology, Inc. Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions
CA2757717C (en) 2009-04-06 2018-09-04 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation
WO2010117941A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
EP3354753B1 (en) 2009-04-06 2020-02-12 Vanda Pharmaceuticals Inc. Method of treatment based on polymorphisms of the kcnq1 gene
WO2010117943A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
WO2012032532A1 (en) * 2010-09-07 2012-03-15 Symed Labs Limited "processes for the preparation of 4'-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3'-methoxyacetophenone and intermediates thereof"
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
EP2825167B1 (en) 2012-03-14 2018-05-09 Vanda Pharmaceuticals Inc. An iloperidone metabolite for use in the treatment of psychiatric disorders
US10441580B2 (en) 2015-02-17 2019-10-15 Vanda Pharmaceuticals, Inc. Iloperidone for the treatment of schizophrenia
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
IL285721B2 (en) 2019-02-21 2025-03-01 Obi Pharma Inc Methods of making high enantioselective secondary alcohols
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
EP4507698A1 (en) 2022-04-13 2025-02-19 Vanda Pharmaceuticals Inc. Treatment of parkinson's disease and parkinson's disease psychosis
CN120390640A (zh) 2022-12-19 2025-07-29 万达制药公司 治疗双相i型障碍和精神分裂症的伊潘立酮的给药方案
WO2024249952A1 (en) 2023-06-02 2024-12-05 Vanda Pharmaceuticals Inc. Method of treatment with iloperidone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
ES2076253T3 (es) 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
JPH05286868A (ja) 1992-04-03 1993-11-02 Kiyoshi Okawa 制がん剤複合体およびそのスクリーニング法
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
ES2149742T1 (es) * 1997-07-03 2000-11-16 Asahi Chemical Ind Nuevos compuestos triciclicos que tienen anillos saturados y composiciones medicinales que contienen los mismos.
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.

Also Published As

Publication number Publication date
HK1156309A1 (en) 2012-09-07
DK2305656T3 (da) 2013-02-11
HK1066536A1 (en) 2005-03-24
EP2305656B1 (en) 2012-10-24
ES2370634T3 (es) 2011-12-21
JP2005504783A (ja) 2005-02-17
PT2305656E (pt) 2013-01-10
ATE518845T1 (de) 2011-08-15
CY1113550T1 (el) 2016-06-22
US20130296366A1 (en) 2013-11-07
US7977356B2 (en) 2011-07-12
EP1425272B1 (en) 2011-08-03
US20110201646A1 (en) 2011-08-18
JP2015227368A (ja) 2015-12-17
US8314129B2 (en) 2012-11-20
ES2398434T3 (es) 2013-03-19
ES2398434T8 (es) 2017-10-09
DK1425272T3 (da) 2011-11-21
US20090176739A1 (en) 2009-07-09
EP1425272A1 (en) 2004-06-09
JP2013227335A (ja) 2013-11-07
PT1425272E (pt) 2011-10-19
JP2015214577A (ja) 2015-12-03
WO2003020707A1 (en) 2003-03-13
JP2010100633A (ja) 2010-05-06
EP2305656A1 (en) 2011-04-06
JP2013116905A (ja) 2013-06-13
US20050020632A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
CY1113550T1 (el) Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης
NO20051965L (no) Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.
HRP20080226T3 (en) Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
NO20051527L (no) 3-(sulfonamidoetyl) -indol-derivater for anvendelse som glukocorticoid-mimetica ved behandling av inflammatoriske, allergiske og proliferative sykdommer.
ATE425964T1 (de) Cyclische amidinderivate
NO20062370L (no) Amidderivater
NO20091892L (no) Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre
PE20080360A1 (es) Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3
HRP20080446T3 (en) Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
ATE498600T1 (de) Inden derivate als pharmazeutika
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
ATE360612T1 (de) In 4-stellung substituierte piperidinderivate
DE602004009079D1 (de) Carbostyril-derivative zur beschleunigten speichelabsonderung
NO20054225L (no) Benzamid-derivater som oksytocin-agonister og vasopressin-antagonister
DE50005937D1 (de) 3-(4,5-dihydroisoxazol-5-yl)benzoylpyrazole
MXPA03010442A (es) Derivados de 4-(fenil-(piperidin-4-il)-amino)-benzamida y sus usos para tratamiento de dolor, ansiedad o desordenes gastrointestinales.
NO20072587L (no) Fenyldiazepankarboksamider og anilerte fenylpiperazinkarboksamider inneholdende oksygen og benyttet som dopamin D3 antagonister
EA200401290A1 (ru) НЕКОТОРЫЕ ПРОИЗВОДНЫЕ 1-(D-ЦИКЛОПРОПИЛГЛИЦИНИЛ)-4-(ПИПЕРИДИН-4-ИЛ)ПИПЕРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СЕРИНПРОТЕАЗЫ ФАКТОРА Xa
DK1245564T3 (da) Benzamidinderivater
SE0102809D0 (sv) Novel compounds
ATE389326T1 (de) 3-cyclopropyl-4-(3-amino-2-methylbenzoyl)pyrazo e und ihre verwendung als herbizide
DE602005005638D1 (de) 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-on-derivate als pde4-inhibitoren
NO20056188L (no) Anvendelse av en c-Abl-, PDGF-R- eller c-kit-tyrosinkinaseinhibitor for behandling av diabetes
DE50014393D1 (de) Cyclopropyl-anellierte 3-(4,5-dihydroisoxazol-3-yl)-substituierte benzoylpyrazole als herbizide
AR026673A1 (es) Benzoilpirazoles sustituidos por 3-(4,5-dihidroisoxazol-3-ilo)